Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs

Editorial Checklist Reviewed
Sep 15 2009NewsGuard 100/100 Score

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.

The presentations will be available via live audio webcast on the Company’s website. Archived replays will also be located on the Company’s site following the events. The presentation date and time is subject to change. The most up to date information will be available on the Company’s website.

Source:

http://www.iderapharma.com/

Posted in: Pharmaceutical News

Tags: , , , , , ,

Comments (0)

Suggested Reading

Study uncovers biological drivers of plasma proteins, offering new insights for disease biomarkers and drug discovery
PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease
USC and Autobahn Labs team up to advance breakthrough drug research
Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery
The Key Role of iPSC-Derived Microglia in Research and Drug Discovery
New deep-learning framework identifies non-addictive pain relief options
Ohio State's novel DHODH inhibitor enters first human trials
Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
KiNet web portal enhances study of kinase functions in cellular signaling pathways